Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions
暂无分享,去创建一个
[1] V. Cuervas-Mons,et al. Baseline NS5A resistance associated substitutions may impair DAA response in real‐world hepatitis C patients , 2018, Journal of medical virology.
[2] T. Hassanein,et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. , 2017, Journal of hepatology.
[3] H. Mo,et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. , 2017, Journal of hepatology.
[4] Paulina Deming,et al. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection , 2017, Pharmacotherapy.
[5] M. Manns,et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.
[6] Liangjun Lu,et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir , 2017, Antimicrobial Agents and Chemotherapy.
[7] Jean-Michel Pawlotsky,et al. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.
[8] H. Mo,et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein , 2016, Antimicrobial Agents and Chemotherapy.
[9] M. Ciotti,et al. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents , 2016, Hepatology.
[10] J. A. Patino-Galindo,et al. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6 , 2016, Antimicrobial Agents and Chemotherapy.
[11] P. Hu,et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data , 2016, Scientific Reports.
[12] Christoph Sarrazin,et al. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.
[13] K. Reddy,et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.
[14] T. Berg,et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.
[15] C. Stedman,et al. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection , 2015, Annals of Internal Medicine.
[16] Tara L. Kieffer,et al. Hepatitis C virus drug resistance–associated substitutions: State of the art summary , 2015, Hepatology.
[17] P. Thuluvath,et al. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study , 2015, Hepatology.
[18] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[19] Sebastian Lambert,et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors , 2014, Protein science : a publication of the Protein Society.
[20] C. Rice,et al. Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.
[21] F. Mcphee,et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[22] Sergei L. Kosakovsky Pond,et al. Detecting Individual Sites Subject to Episodic Diversifying Selection , 2012, PLoS genetics.
[23] R. Nettles,et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS‐790052 , 2012, Hepatology.
[24] F. Poordad,et al. Treatment of hepatitis C , 2003 .